Registration to this Virtual Event is free of charge and gives you 180 days access. You will be sent details of how to access the event via email after registration.
For more information please click here.
 | 3D Organoids-Based High Content Screening
Xavier Gidrol, CEA Grenoble
We will describe the development and use of MEMS (MicroElectroMechanical Systems) to systematically analyze the phenotypic consequences of genetic perturbations (RNAi-based HCS) in 3D organoids cultures. More specifically we address the following issue: What are the genetic and microenvironmental determinants that control prostate carcinogenesis?
| |
 | Complex Tissue Models that Mimic the Tumour Microenvironment, Heterogeneity, Invasion, Drug Sensitivity and Progression of Cancers
Matthias Nees, VTT Technical Research Centre
This presentation will demonstrate the use of statistical and mathematical algorithms to quantitatively assess the most relevant and significant morphometric changes in tissue architecture upon drug exposure and genetic modifications.
| |
 | Complex Tissue Models that Mimic the Tumour Microenvironment, Heterogeneity, Invasion, Drug Sensitivity and Progression of Cancers
Matthias Nees, University of Turku
This presentation will demonstrate the use of statistical and mathematical algorithms to quantitatively assess the most relevant and significant morphometric changes in tissue architecture upon drug exposure and genetic modifications.
| |
 | High Content Imaging in Chronic Kidney Disease
Douglas Ross-Thriepland, Astrazeneca
The application of high content imaging and phenotypic screening in order to identify novel targets for the treatment of diabetic nephropathy associated kidney damage.
| |
 | Imaging in 3 Dimensions; Paradigms and Pitfalls
Steven Titus, NIH - NCATS
Three dimensional imaging and analysis are becoming standard practice within the field of High Content Imaging. During the presentation, I will summarize many of the current trends and observations encountered with 3D imaging experiments from a practical perspective.
| |
 | Phenotypic Drug Discovery – The Move from High Content to High Impact Screening
Beverley Isherwood, AstraZeneca
In recent years, phenotypic drug discovery (PDD) has received a lot of attention in industry and academia and the scientific community has started to believe that phenotypic readouts nicely complement the more conventional approaches of target-based drug discovery (TDD). In this presentation, we will describe our PDD experience from implementing and running this approach over several years, we will review the current status, show the synergies of both approaches, and we will give an outlook on future trends.
| |
 | Screening and Profiling of Cancer Therapeutics in Primary and Stem Cell-derived Human 3D Tissues
Leo Price, Leiden University
We describe the combination of 3D culture of human tissues with ultra-high content 3D image analysis to screen compound libraries and identify and profile novel cancer therapeutics.
| |
 | Screening and Profiling of Cancer Therapeutics in Primary and Stem Cell-derived Human 3D Tissues
Leo Price, Ocello B.V
We describe the combination of 3D culture of human tissues with ultra-high content 3D image analysis to screen compound libraries and identify and profile novel cancer therapeutics.
| |
| Single Cell Analysis for HCS
Thierry Dorval, Institut Pasteur Korea
High content imaging platforms are giving the opportunity to monitor cellular phenotype at the level of individual object. We present case studies where heterogeneity is used at its advantage to extend phenotypic readouts.
| |
 | Single Cell Analysis for HCS
Thierry Dorval, Servier
High content imaging platforms are giving the opportunity to monitor cellular phenotype at the level of individual object. We present case studies where heterogeneity is used at its advantage to extend phenotypic readouts.
| |
 | Towards Understanding Phenotypic Readouts - Utilizing Multiple Types of Chemical and Biological Data to Rationalize Compound Action
Andreas Bender, The University of Cambridge
In our work, we explore how chemical and biological information from different domains -such as ligand-target prediction, microarray readouts, and RNA-Seq information - can be used separately, or in combination, in order to understand the mode of action of a compound (such as a hit from high-content screening) in greater detail.
| |
Back to the top
|
